Jaguar Animal Health (NASDAQ:JAGX) Stock Crosses Below Fifty Day Moving Average – What’s Next?

Jaguar Animal Health, Inc. (NASDAQ:JAGX) passed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $0.93 and traded as low as $0.59. Jaguar Animal Health shares last traded at $0.6320, with a volume of 215,884 shares changing hands.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on JAGX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Thursday, January 22nd. Wall Street Zen lowered Jaguar Animal Health to a “strong sell” rating in a research note on Friday, January 23rd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $60.00.

Jaguar Animal Health Stock Up 7.9%

The firm has a market capitalization of $2.36 million, a price-to-earnings ratio of -0.02 and a beta of 0.09. The firm has a fifty day moving average price of $0.93 and a 200 day moving average price of $1.53. The company has a current ratio of 0.81, a quick ratio of 0.52 and a debt-to-equity ratio of 4.08.

Jaguar Animal Health (NASDAQ:JAGX) last released its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($6.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.08) by ($1.20). The business had revenue of $3.08 million for the quarter, compared to analyst estimates of $3.73 million. Jaguar Animal Health had a negative net margin of 341.90% and a negative return on equity of 1,194.94%. Sell-side analysts anticipate that Jaguar Animal Health, Inc. will post -0.8 EPS for the current fiscal year.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.